Mutant KRAS at the Heart of Tumor Immune Evasion

Febe van Maldegem*, Julian Downward

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.

Original languageEnglish
Pages (from-to)14-16
Number of pages3
Issue number1
Publication statusPublished - 14 Jan 2020
Externally publishedYes

Cite this